BRIEF published on 12/11/2024 at 12:13, 1 year 4 months ago Threshold crossing by Bpifrance in ABIONYX PHARMA Voting Rights Actions Threshold Crossing Bpifrance ABIONYX
BRIEF published on 12/10/2024 at 10:51, 1 year 4 months ago Threshold crossing by Cyrille Tupin at ABIONYX PHARMA Voting Rights Actions Threshold Crossing ABIONYX Pharma Cyrille Tupin
BRIEF published on 11/14/2024 at 19:05, 1 year 5 months ago ABIONYX Pharma: Third quarter 2024 financial report Biotechnology Treasury Turnover Q3 2024 ABIONYX Pharma
PRESS RELEASE published on 11/14/2024 at 19:00, 1 year 5 months ago Quarterly financial reporting / Third quarter financial report ABIONYX Pharma reports Q3 2024 revenue of €3.4m and cash position of €4.1m before IRIS Pharma's CIR receipt. General Meeting on November 28, 2024, at 2.00 pm CET Cash Position General Meeting Biotech Company ABIONYX Pharma Revenue Update
BRIEF published on 10/24/2024 at 19:35, 1 year 6 months ago ABIONYX Pharma presents the results of the RACERS study ABIONYX Pharma CER-001 Brain Fog Kidney Week Neuroinflammation
PRESS RELEASE published on 10/24/2024 at 19:30, 1 year 6 months ago Inside Information / Other news releases ABIONYX Pharma's RACERS study on CER-001 shows positive impact on cognitive impairment in brain-fog patients, presenting new clinical results at ASN 2024 Annual Meeting. Potential treatment for neuroinflammation ABIONYX Pharma CER-001 Brain-fog Neuroinflammation RACERS Study
BRIEF published on 10/21/2024 at 20:05, 1 year 6 months ago ABIONYX Pharma receives positive EMA opinion for CER-001 ABIONYX Pharma CER-001 EMA AMM LCAT Deficiency
PRESS RELEASE published on 10/21/2024 at 20:00, 1 year 6 months ago Inside Information / Other news releases ABIONYX Pharma receives positive feedback from EMA for CER-001 in LCAT Deficiency, allowing submission of data from 2 prospective process validation batches for MAA manufacturing ABIONYX Pharma CER-001 EMA LCAT Deficiency Process Validation Batches
BRIEF published on 08/22/2024 at 18:05, 1 year 8 months ago ABIONYX Pharma: Review of the first half of 2024 Biotechnology Fundraising Treasury Turnover ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 1 year 8 months ago Inside Information / Other news releases ABIONYX Pharma reports €2.4m sales and €5.3m cash position for H1 2024, focused on innovative therapies. Raised €3.4m for sepsis program in the US Sales Cash Position Innovative Therapies ABIONYX Pharma Sepsis
Published on 04/27/2026 at 15:00, 2 hours 6 minutes ago Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split
Published on 04/27/2026 at 14:25, 2 hours 41 minutes ago Guanajuato Silver Files Technical Report for Bolanitos Mine
Published on 04/27/2026 at 14:00, 3 hours 6 minutes ago GameSquare Announces Record Q1 2026 Bookings of Over $10 Million for its GameSquare Experiences Division
Published on 04/27/2026 at 13:00, 4 hours 6 minutes ago Core Silver and Arcus Development Group Enter into a Binding Letter of Intent for a Business Combination Transaction and Sign a Definitive Option Agreement for the Touleary Project
Published on 04/27/2026 at 13:00, 4 hours 6 minutes ago Eagle Plains Announces Letter of Intent with Pacific Bay Minerals for the Haskins Critical Minerals Project, British Columbia
Published on 04/27/2026 at 16:36, 29 minutes ago EQS-Adhoc: electrovac AG sets final offer price for its initial public offering at EUR 7.80 per share
Published on 04/27/2026 at 15:40, 1 hour 25 minutes ago Zentiva appeals EU court decision on Urban Wastewater Directive
Published on 04/27/2026 at 15:09, 1 hour 57 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 04/27/2026 at 15:08, 1 hour 57 minutes ago Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 04/27/2026 at 15:00, 2 hours 5 minutes ago EQS-Adhoc: Haier Smart Home Co.,Ltd.: Buy-back Offer of D-Shares
Published on 04/27/2026 at 11:42, 5 hours 23 minutes ago Description of the share repurchase program authorized by the Combined General Meeting of the shareholders of April 24, 2026
Published on 04/24/2026 at 17:45, 2 days 23 hours ago Imerys-04-2026-information-share-capital-and-voting-rights-as-of-31-March-2026
Published on 04/24/2026 at 16:37, 3 days ago Availability of the 2025 Universal Registration Document (URD)
Published on 04/23/2026 at 19:27, 3 days 21 hours ago Annual Shareholders' Meeting 2026 - Conditions of availability of the preparatory documents
